Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
ASC-60 by Sagimet Biosciences for Solid Tumor: Likelihood of Approval
ASC-60 is under clinical development by Sagimet Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...